Showing results (1211-1220 of 2,824) with videos related to

Sort By:
Pageof 283
Cytotherapy|May 18, 2019
Current good manufacturing practices-compliant manufacture and measurement of biotin-labeled red blood cellsAlbert D Donnenberg, Tamir Kanias, Darrell J Triulzi, et al.
Cytotherapy|August 21, 2018
Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free mediumYuriko Nishiyama-Fujita, A I Kawana-Tachikawa, Toshiaki Ono, et al.
Cytotherapy|May 30, 2019
Identification of senescent cells in multipotent mesenchymal stromal cell cultures: Current methods and future directionsWeichao Zhai, Derrick Yong, Jehan Jomaa El-Jawhari, et al.
Cytotherapy|October 15, 2018
Proceedings of the signature series symposium "cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies-promise, facts and fantasy," international society for cellular therapies, montreal, canada, may 2, 2018Nicolas S Piuzzi, Massimo Dominici, Marc Long, et al.
Cytotherapy|October 16, 2018
Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trialMohsen Emadedin, Narges Labibzadeh, Maede Ghorbani Liastani, et al.
Cytotherapy|January 22, 2022
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical useElisa Gotti, Sarah Tettamanti, Silvia Zaninelli, et al.
Cytotherapy|September 6, 2018
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapyJoana M Murad, Susanne H Baumeister, Lillian Werner, et al.
Cytotherapy|September 2, 2018
Production via good manufacturing practice of exofucosylated human mesenchymal stromal cells for clinical applicationsMaría Dolores López-Lucas, Gisela Pachón-Peña, Ana María García-Hernández, et al.
Cytotherapy|October 13, 2018
Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cellsSergey N Zolov, Skyler P Rietberg, Challice L Bonifant
Cytotherapy|October 17, 2021
The safety and efficacy of mesenchymal stem cell therapy in diabetic lower extremity vascular disease: a meta-analysis and systematic reviewLewei Jin, Xiancheng Wang, Zhihua Qiao, et al.
Pageof 283